Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04117698
Other study ID # P160912J
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date November 1, 2019
Est. completion date May 1, 2023

Study information

Verified date October 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Georges Sélim TRAD
Phone +33149095642
Email salim.trad@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Uveitis accounts for 15% of the causes of legal blindness. The etiological diagnosis of uveitis is difficult because of the poor bacteriological performance of aqueous or vitreous fluid analysis. At the end of a medical and paramedical check-up, oriented by the typology of uveitis, a clinical situation is frequently encountered: idiopathic uveitis with a Quantiferon test (QFN) positive orienting to an old or recent contact with tuberculosis. Ocular tuberculosis is often characterized by a partial and transient response to corticosteroid therapy (local or general), due to predominant hypersensitivity phenomena and low inoculum. Therefore, antitubercular treatment is recommended for idiopathic posterior uveitis with positive QFN. This treatment of 6-9 months has shown, in combination with systemic corticosteroids, its effectiveness on ocular inflammation and significant decrease in recurrence frequency.

For previous uveitis with QFN positive, there is no study or recommendation in the low endemic countries on the indication of anti-tuberculosis drugs and practices are variable.

Tuberculous anterior uveitis is distinguished by high rate of relapses and chronic uveitis upon discontinuation of topic corticosteroid therapy that exposes to broad posterior synechiae leading to an ocular functional impairment. Optimizing the management of recurrent anterior uveitis is therefore crucial.

The aim of this prospective, randomized, controlled, open, two parallel arm trial is to compared antitubercular treatment "add-on "of local corticosteroid therapy to Local Corticosteroid Therapy Only in patients with recurrent or chronic anterior uveitis.

Primary outcome is the treatment succes defined as uveitis recovery at 3 months and the absence of recurrence at 18 months of follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 116
Est. completion date May 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age=18 years.

2. For women of childbearing age (unless confirmed postmenopausal or sterile), ßHCG negative.

3. For subjects of childbearing age, the willingness to use adequate contraceptive measures to prevent the subject or partner of the subject from becoming pregnant during the first 6 months of the study in case of randomization in the experimental group.

4. Recurrent anterior Uveitis (= 2 episodes of ocular inflammation within the past 2 years before inclusion with a free-interval of at least 3 months between ocular inflammations, patients with a second episode of ocular inflammation may be included in the study) or chronic anterior Uveitis (persistence of ocular inflammation = partial response after 3 months of well-conducted local treatment) .

5. Positive Quantiferon test (QFN) performed after the first episode of ocular inflammation (accepted tests: Quantiferon-TB-Gold, Quantiferon-TB-Gold in tube or Quantiferon plus) with a threshold = 1 IU / ml or associated with a positive ELISPOT test if the QFN level is between 0.7 and 1UI / l.

6. Absence of other etiology that may explain anterior uveitis during etiological investigations

1. Serology of herpes group viruses (HSV,, CMV, VZV) negative or old immunity (achieved after the first episode of ocular inflammation).

2. TPHA, negative VDRL (performed after the 1st episode of ocular inflammation).

3. Serologies HIV, HBV and HCV, negative (performed within the 3 months before inclusion).

4. Negative Lyme serology (performed after the first episode of ocular inflammation) or medical history not supporting this etiology

5. HLA B27 negative (achieved after the first episode of ocular inflammation) if recurrent or non-granulomatous uveitis

6. Negative PCR from anterior chamber fluid for Herpes group viruses, Toxoplasma gondii and Mycobacterium tuberculosis if severe inflammation (Tyndall Cellular and / or Flare> 2+) and / or posterior synechiae .

7. Non-contributory pulmonary imaging (performed within the last month before inclusion) (radiography or chest CT scan left to the discretion of the clinician).

Note: The non-granulomatous character uveitis during clinical examination is not an exclusion criterion.

7. If 4+ severity score (Tyndall and / or Flare of aqueous humor) an expert opinion is required (internist / ophthalmologist pair): with no indication to initiate an anti-tuberculosis treatment without delay.

8. Signature of informed consent to participate in the study.

9. Patients affiliated to the French health care insurance

Exclusion Criteria:

1. Weight strictly less than 50 kg

2. Weight strictly greater than 185 kg

3. History of cancer 5 years before inclusion (except in situ cervical cancer or non-metastatic baso or squamous cell carcinoma) or progressive malignant hemopathy.

4. Liver failure or ALTgreater than three times the normal value or severe renal impairment (GFR <30ml / min).

5. Neutropenia <1000 / mm3, Thrombocytopenia <50,000 / mm3, Hemoglobin <8g / dL

6. Pulmonary or active visceral tuberculosis.

7. Associated posterior and intermediate uveitis (indication for almost constant systemic corticosteroid therapy, and de facto contraindication to a control arm without TB treatment).

8. Monophthalmic patient

9. Intervention with general anesthesia during the first 6 months

10. Clinical presentation of acute anterior uveitis type HLA B27.

11. History of tuberculous disease treated.

12. Systemic corticosteroid therapy or immunosuppressive therapy received within 3 months before inclusion.

13. Local corticotherapy received for more than 15 days in the 2 months before inclusion.

14. Hypersensitivity to the family of rifamycin, isoniazid, pyrazinamide and known ethambutol or to any of the excipients present in the medicinal products of this trial (presence, in particular, of excipients with known effect: sucrose, sodium)

15. Known hypersensitivity to fluorometholone or any of the excipients, in particular with benzalkonium chloride.

16. Known hypersensitivity to dexamethasone phosphate or to any of the excipients

17. Known hypersensitivity to tropicamide, atropine or its derivatives,

18. Known hypersensitivity to phenylephrine, thiomersal

19. Antecedent of optic neuritis.

20. Patients with wheat allergy (other than celiac disease).

21. Association with praziquantel, voriconazole, which cannot be interrupted for clinical research study.

22. Porphyries known.

23. Patient under Valaciclovir

24. Hyperuricemic subjects with symptomatic joint involvement

25. Eye infections not controlled by antiinfectives, such as:

- acute purulent bacterial infections, including Pseudomonas and Mycobacteria infections,

- fungal infections,

- epithelial keratitis due to Herpes simplex virus (dendritic keratitis), vaccinia virus, varicella zoster virus and most other viral infections of the cornea and conjunctiva,

- amoebic keratitis,

26. Perforation, ulceration and corneal injury associated with incomplete reepithelialization

27. Known ocular hypertension caused by glucocorticoids, risk of angle closure glaucoma,

28. Pregnancy or breastfeeding.

29. Psychiatric disorder and / or patient under guardianship.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Antitubercular treatment (RIFATER ©)
Treatment of ocular inflammation by "antitubercular treatment " add-on "of local corticosteroid therapy" comprising: RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months associated with a treatment similar to the control group.
Ethambutol
Ethambutol
RIFINAH ©
RIFINAH ©

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary Success Success is defined by uveitis recovery at 3 months and the absence of recurrence at 18 months of follow-up.
The intensity of the ocular inflammation will be evaluated using the Standardization of Uveitis Nomenclature (SUN) classification (score of cellular Tyndall and "Flare" of the aqueous humor) Failure is therefore defined as failure to recovery at 3 months of anterior uveitis or recurrence at 18 months.
at 18 months
Secondary Proportion of patients having developped neutropenia Neutropenia will be defined as PNN less than 1000 mm3 at 6 months
Secondary Proportion of patients having developped hepatitis with clinical signs Hepatitis will be defined as hepatitis with clinical signs and ALT greater than 3 times the normal value at 6 months
Secondary Proportion of patients having developped severe hepatitis Severe hepatitis will be defined will be defined as ALT greater than 5 times the normal value at 6 months
Secondary Proportion of patients having developped moderate or severe skin allergy at 6 months
Secondary Proportion of patients having developped neuritis or optic atrophy at 6 months
Secondary Proportion of patients having developped acute renal failure at 6 months
Secondary Proportion of patients having developped peripheral neuropathy at 6 months
Secondary Proportion of patients having developped other adverse effects at 6 months
Secondary Proportion of patients with recurrence between 3 months and 18 months
Secondary Prevalence of failure at 12 months post-treatment
Secondary Cumulative incidence of episodes of ocular inflammation at 18 months
Secondary Cumulative number of anterior uveitis episodes at 18 months
Secondary Tyndall score at 1 month
Secondary Flare's score at 1 month
Secondary Tyndall score at 2 months
Secondary Flare's score at 2 months
Secondary Tyndall score at 3 months
Secondary Flare's score at 3 months
Secondary Tyndall score at 6 months
Secondary Flare's score at 6 months
Secondary Tyndall score at 12 months
Secondary Flare's score at 12 months
Secondary Tyndall score at 15 months
Secondary Flare's score at 15 months
Secondary Tyndall score at 18 months
Secondary Flare's score at 18 months
Secondary Proportion of patients who developed or worsened a decrease in visual acuity at 18 months
Secondary Proportion of patients who developed or worsened a decrease in visual acuity at 3 months
Secondary Proportion of patients who developed or worsened a decrease in visual acuity at 6 months
Secondary Proportion of patients who developed or worsened a decrease in visual acuity at 12 months
Secondary Proportion of patients who developed or worsened a decrease in visual acuity at 15 months
Secondary Proportion of patients who developed or worsened broad posterior synechiae at 3 months
Secondary Proportion of patients who developed or worsened broad posterior synechiae at 6 months
Secondary Proportion of patients who developed or worsened broad posterior synechiae at 12 months
Secondary Proportion of patients who developed or worsened broad posterior synechiae at 15 months
Secondary Proportion of patients who developed a glaucoma at 18 months
Secondary Proportion of patients who developed a glaucoma at 3 months
Secondary Proportion of patients who developed a glaucoma at 6 months
Secondary Proportion of patients who developed a glaucoma at 12 months
Secondary Proportion of patients who developed a glaucoma at 15 months
Secondary Proportion of patients who developed a cataract at 18 months
Secondary Proportion of patients who developed a cataract at 3 months
Secondary Proportion of patients who developed a cataract at 6 months
Secondary Proportion of patients who developed a cataract at 12 months
Secondary Proportion of patients who developed a cataract at 15 months
See also
  Status Clinical Trial Phase
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Completed NCT01978015 - Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Phase 4
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT05649111 - A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification Phase 4
Not yet recruiting NCT05984758 - Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis N/A
Completed NCT00694135 - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis Phase 2
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Not yet recruiting NCT03576898 - Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis Phase 2/Phase 3
Completed NCT00404885 - A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Phase 3
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Recruiting NCT05015335 - The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage Phase 4
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3